Huntsworth Health has delivered a strong financial performance in the first half of the year, delivering a revenue total of 41.5 million pounds.

This represented an 18 percent year-on-year increase, or an 11.5 percent rise on a like-for-like basis. Meanwhile, the business' operating margin for the six months was 19.4 percent, up from 18.7 percent during the first half of 2015.

“Huntsworth Health has experienced double-digit growth during the first half of 2016, with the unit acting as one of the wider Huntsworth group's key growth drivers.“

The health division of the Huntsworth group continued to perform well above industry averages, with growth driven by the US market, where its Evoke Health, ApotheCom and Tonic Life Communications subsidiaries are performing strongly.

New business momentum also remained solid with a number of recent major global wins from an expanded client base that now includes genomics, diagnostics and medical device companies.

Parent company Huntsworth cited the strong performance of Huntsworth Health as one of the main reasons it was able to deliver a 21 percent improvement in headline profits before tax for the half-year.

Paul Taaffe, chief executive officer of Huntsworth, said: "Business momentum in Huntsworth Health remains strong, especially in the US, which will offset the impact that the Grayling restructure imposes on growth and any potential fallout from the uncertainty created by [Brexit]."